<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYOSCYAMINE SULFATE</span><br/>(hye-oh-sye'a-meen)<br/><span class="topboxtradename">Anaspaz, </span><span class="topboxtradename">Cystospaz, </span><span class="topboxtradename">Levsin, </span><span class="topboxtradename">Levsinex, </span><span class="topboxtradename">NuLev<br/></span><b>Classifications:</b> <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antimuscarinic</span>; <span class="classification">antispasmodic</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.125 mg, 0.150 mg tablets; 0.125 mg sublingual tablets; 0.375 sustained release capsules; 0.125 mg orally disintegrating tablet 0.125 mg/mL oral solution; 0.125 mg/5 mL elixir; 0.5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Extremely potent belladonna alkaloid with anticholinergic and antispasmodic activity. Anticholinergic effect chiefly related
         to the levo isomer.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Anticholinergic and antispasmodic action is produced by competitive inhibition of acetylcholine at the parasympathetic neuroeffector
         junctions.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>GI tract disorders caused by spasm and hypermotility, as conjunct therapy with diet and antacids for peptic ulcer management,
         and as an aid in the control of gastric hypersecretion and intestinal hypermotility. Also symptomatic relief of biliary and
         renal colic, as a "drying agent" to relieve symptoms of acute rhinitis, to control preanesthesia salivation and respiratory
         tract secretions, to treat symptoms of parkinsonism, and to reduce pain and hypersecretion in pancreatitis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to belladonna alkaloids, narrow-angle glaucoma, prostatic hypertrophy, obstructive diseases of GI or GU tract,
         paralytic ileus or intestinal atony, myasthenia gravis; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Diabetes mellitus, cardiac disease; pregnancy (category C).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">GI Spasms</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM/SC</span> 0.250.5 mg q6h <span class="rdroute">PO/SL</span> 0.1250.25 mg t.i.d. or q.i.d. prn<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>212 y</i>, 0.06250.125 mg q4h prn (max: 0.75 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Dose for older adults may need to be less than the standard adult dose. Observe patient carefully for signs of paradoxic reactions.
            			
         </li>
</ul><span class="adminroutetype">Oral</span><br/><ul>
<li>Give preparations about 1 h before meals and at bedtime (at least 2 h after last meal).</li>
<li>Ensure that sustained release form of drug is not chewed or crushed. It must be swallowed whole.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 60 sec.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, unusual tiredness or weakness, confusion, <span class="speceff-common">drowsiness,</span> excitement in older adult patients. <span class="typehead">CV:</span> Palpitations, tachycardia. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Blurred vision,</span> increased intraocular tension, cycloplegia, mydriasis. <span class="typehead">GI:</span>
<span class="speceff-common">Dry mouth, constipation,</span> paralytic ileus. <span class="typehead">Other:</span>
<span class="speceff-common">Urinary retention,</span> anhidrosis, suppression of lactation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b> Amantadine,</b>
<span class="classification">antihistamines</span>, <span class="classification">tricyclic anti-depressants</span>, <b>quinidine,</b>
<b>disopyramide,</b>
<b>procainamide</b> add anticholinergic effects; decreases <b>levodopa</b> effects; <b>methotrimeprazine</b> may precipitate extrapyramidal effects; decreases antipsychotic effects of <span class="classification">phenothiazines</span> (decreased absorption). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from all administration sites. <span class="typehead">Onset:</span> 23 min IV; 2030 min PO. <span class="typehead">Peak:</span> 1530 min IV; 3060 min PO. <span class="typehead"> Duration:</span>  46 h (up to 12 h with sustained release form). <span class="typehead">Distribution:</span> Distributed in most body tissues; crosses bloodbrain barrier and placenta; distributed in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead"> Half-Life:</span> 3.513 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor bowel elimination; may cause constipation.</li>
<li>Monitor urinary output.</li>
<li>Lessen risk of urinary retention by having patient void prior to each dose.</li>
<li>Assess for dry mouth and recommend good practices of oral hygiene.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid excessive exposure to high temperatures; drug-induced heatstroke can develop.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Use dark glasses if experiencing blurred vision, but if this adverse effect persists, notify physician for dose adjustment
            or possible drug change.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>